{
  "schema_version": "1.0",
  "type": "article",
  "title": "AstraZeneca's $1.5B AI Deal Pays 2.7% Up Front",
  "url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.md",
  "lang": "en",
  "date": "2026-10-21",
  "publish_at": "2026-10-21T08:00:00+08:00",
  "updated_at": "2026-10-21",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "AstraZeneca",
    "insitro",
    "AI drug discovery",
    "Isomorphic Labs",
    "MASH"
  ],
  "summary": "On Oct 15, AstraZeneca signed insitro to an AI deal worth up to $1.5B, paying $40M at signing. Five AI deals pay 1-3% up front; Takeda paid $4B for a drug with Phase 2 data. Targets are tickets; human data is leverage.",
  "key_points": [
    "AstraZeneca signed an AI target-discovery collaboration with insitro for MASH and cardiomyopathies on October 15, 2026, paying $40 million up front with up to about $1.46 billion in milestones and single-digit royalties; the upfront is about 2.7% of the roughly $1.5 billion headline.",
    "Five AI drug discovery deals all paid 1% to 3% up front: Lilly × Isomorphic Labs 2.6% and Novartis × Isomorphic Labs 3.0% (January 2024), AstraZeneca × CSPC 2.1% (June 2025), and Roche × Recursion 1.25% (December 2021).",
    "By contrast, Takeda paid about $4 billion up front in February 2023 for Nimbus's TYK2 inhibitor TAK-279, which had Phase 2b data: about 67% of the total and 100 times AstraZeneca's upfront to insitro; insitro's own liver programs are expected to enter human trials in early 2027."
  ],
  "facts": [
    {
      "claim": "AstraZeneca × insitro upfront at signing",
      "value": 40,
      "unit": "USD million",
      "as_of": "2026-10-15",
      "source": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "claim": "AstraZeneca × insitro milestone cap",
      "value": 1.46,
      "unit": "USD billion",
      "as_of": "2026-10-15",
      "source": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "claim": "AstraZeneca × insitro headline deal value",
      "value": 1.5,
      "unit": "USD billion",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "AstraZeneca × insitro royalty tier",
      "value": "single digits",
      "unit": "%",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "AstraZeneca × insitro upfront share of headline ($40M / ~$1.5B)",
      "value": 2.7,
      "unit": "%",
      "as_of": "2026-10-15",
      "source": "https://qz.com/astrazeneca-insitro-ai-drug-discovery-liver-heart-101526"
    },
    {
      "claim": "Daphne Koller years on Stanford faculty",
      "value": 18,
      "unit": "years",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "Gilead × insitro NASH upfront (2019)",
      "value": 15,
      "unit": "USD million",
      "as_of": "2019-04-16",
      "source": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "claim": "Gilead × insitro 2019 royalty tier",
      "value": "low double digits",
      "unit": "%",
      "as_of": "2019-04-16",
      "source": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "claim": "insitro Series C",
      "value": 400,
      "unit": "USD million",
      "as_of": "2021-03-15",
      "source": "https://www.insitro.com/news/insitro-raises-400-million-in-series-c-financing"
    },
    {
      "claim": "insitro total funding raised",
      "value": "more than 750",
      "unit": "USD million",
      "as_of": "2026-09-08",
      "source": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "claim": "insitro workforce cut, May 2025",
      "value": 22,
      "unit": "%",
      "as_of": "2025-05-09",
      "source": "https://www.biospace.com/job-trends/insitro-cuts-22-of-workforce-extending-runway-into-2027"
    },
    {
      "claim": "insitro lead liver programs expected to enter human trials",
      "value": "early 2027",
      "unit": "date",
      "as_of": "2026-09-08",
      "source": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "claim": "Rezdiffra Q2 2026 net sales",
      "value": 364.3,
      "unit": "USD million",
      "as_of": "2026-07-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Rezdiffra Q2 2026 net sales YoY growth",
      "value": 71,
      "unit": "%",
      "as_of": "2026-07-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Rezdiffra patients on therapy at June 30, 2026",
      "value": "more than 49,000",
      "unit": "patients",
      "as_of": "2026-06-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Wegovy FDA accelerated approval for noncirrhotic MASH",
      "value": "2025-08-15",
      "unit": "date",
      "as_of": "2025-08-15",
      "source": "https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"
    },
    {
      "claim": "Lilly × Isomorphic Labs upfront",
      "value": 45,
      "unit": "USD million",
      "as_of": "2024-01-07",
      "source": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "claim": "Novartis × Isomorphic Labs upfront",
      "value": 37.5,
      "unit": "USD million",
      "as_of": "2024-01-07",
      "source": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "claim": "Roche/Genentech × Recursion upfront",
      "value": 150,
      "unit": "USD million",
      "as_of": "2021-12-07",
      "source": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "claim": "Roche/Genentech × Recursion headline value",
      "value": 12,
      "unit": "USD billion",
      "as_of": "2021-12-07",
      "source": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "claim": "AstraZeneca × CSPC upfront",
      "value": 110,
      "unit": "USD million",
      "as_of": "2025-06-13",
      "source": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "claim": "AstraZeneca × CSPC total (upfront + $1.62B dev + $3.6B sales)",
      "value": 5.33,
      "unit": "USD billion",
      "as_of": "2025-06-13",
      "source": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "claim": "Takeda acquisition of Nimbus TYK2 subsidiary upfront",
      "value": 4,
      "unit": "USD billion",
      "as_of": "2023-02-08",
      "source": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    },
    {
      "claim": "Takeda × Nimbus upfront share of total ($4B / $6B)",
      "value": 67,
      "unit": "%",
      "as_of": "2023-02-08",
      "source": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    }
  ],
  "sections": [
    "01 | A $1.5 billion headline, $40 million at signing",
    "02 | AstraZeneca wants a switch in the liver nobody has pressed",
    "03 | Five AI deals, and every upfront sits between 1% and 3%",
    "04 | With human data, the upfront jumps 100 times",
    "05 | Taiwan's licensing headlines deserve the same ruler",
    "References"
  ],
  "references": [
    {
      "title": "AstraZeneca strikes $40 million AI drug discovery deal with insitro (Reuters",
      "source": "Euronext",
      "date": "2026-10-15",
      "url": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "title": "AstraZeneca signs AI drug discovery deal with insitro",
      "source": "Quartz",
      "date": "2026-10-15",
      "url": "https://qz.com/astrazeneca-insitro-ai-drug-discovery-liver-heart-101526"
    },
    {
      "title": "Insitro's Virtual Human attracts $1.5B MASH deal with Astrazeneca",
      "source": "BioWorld",
      "date": "2026-10-15",
      "url": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "title": "Daphne Koller",
      "source": "Wikipedia",
      "date": "2026-10-17",
      "url": "https://en.wikipedia.org/wiki/Daphne_Koller"
    },
    {
      "title": "Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis",
      "source": "Gilead",
      "date": "2019-04-16",
      "url": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "title": "insitro Raises $400 Million in Series C Financing",
      "source": "insitro",
      "date": "2021-03-15",
      "url": "https://www.insitro.com/news/insitro-raises-400-million-in-series-c-financing"
    },
    {
      "title": "Insitro Cuts 22% of Workforce, Extending Runway Into 2027",
      "source": "BioSpace",
      "date": "2025-05-09",
      "url": "https://www.biospace.com/job-trends/insitro-cuts-22-of-workforce-extending-runway-into-2027"
    },
    {
      "title": "insitro Names Hideo Makimura Chief Medical Officer Ahead of First Clinical Trials",
      "source": "citybiz",
      "date": "2026-09-08",
      "url": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "title": "Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results",
      "source": "Madrigal (SEC 8-K",
      "date": "2026-07-30",
      "url": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "title": "FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH",
      "source": "HCPLive",
      "date": "2025-08-15",
      "url": "https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"
    },
    {
      "title": "Isomorphic inks deals with Eli Lilly and Novartis for drug discovery",
      "source": "TechCrunch",
      "date": "2024-01-07",
      "url": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "title": "Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort",
      "source": "GEN",
      "date": "2021-12-07",
      "url": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "title": "AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research",
      "source": "AstraZeneca",
      "date": "2025-06-13",
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "title": "Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary",
      "source": "Takeda",
      "date": "2023-02-08",
      "url": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    }
  ],
  "images": [
    {
      "alt": "Figure 1｜Rezdiffra and Wegovy hit known switches; insitro hunts the next one for AstraZeneca",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/figure-01.png"
    },
    {
      "alt": "Figure 2｜Five AI drug deals, each paying 1% to 3% up front",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/figure-02.png"
    },
    {
      "alt": "Figure 3｜Same word, \"upfront,\" but the molecule with human data got 100 times more",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/figure-03.png"
    },
    {
      "alt": "Figure 4 | AstraZeneca and insitro divide discovery, development and commercial work",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/figure-04.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront-en/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-21）。AstraZeneca's $1.5B AI Deal Pays 2.7% Up Front。https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront-en.html",
  "disclaimer": "This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.",
  "translations": {}
}